The key condition to monitor is the minimum tender condition (more than 50% of shares). Given the unanimous board recommendation and the significant premium, the offer is likely to succeed. Watch for any competing bids, regulatory challenges beyond HSR, or stockholder litigation that could delay or alter the terms.
Price Chart
Executive Summary
Viatris, through its wholly owned subsidiary Peach Purchaser Sub Inc., has commenced a tender offer to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, representing a ~45% premium over the $25.20 closing price on October 7, 2026 (the last trading day before the merger announcement). The offer is part of a definitive merger agreement signed on October 8, 2026, and is unanimously recommended by Pacira's board. The HSR waiting period has expired, and the offer is not subject to a financing condition. The tender offer expires on November 16, 2026, and will be followed by a second-step merger under Section 251(h) of the DGCL.
Key Financial Metrics
Key Facts
- Offer price: $36.50 per share in cash
- Premium: ~44.8% over the $25.20 closing price on October 7, 2026 (last trading day before announcement)
- Total equity value: approximately $1.65 billion (based on 39,957,678 shares outstanding)
- Total estimated funds required: approximately $554.0 million (including equity awards, convertible notes, and fees)
- HSR waiting period expired on October 29, 2026
- Minimum condition: at least one share more than 50% of outstanding shares must be tendered
- Offer expires: November 16, 2026 at 11:59 p.m. Eastern Time
- No financing condition; Viatris will fund with cash on hand and short-term borrowings
- Pacira board unanimously recommends tender
- Merger will be effected under Section 251(h) of the DGCL without a stockholder vote
- Termination fee payable by Pacira: $62,000,000
- Convertible notes: $287,500,000 aggregate principal amount outstanding
Financial Impact
Total consideration of approximately $1.65 billion for all outstanding shares, plus approximately $554 million for equity awards, convertible notes, and related payments, funded from Viatris cash on hand and short-term borrowings
Risk Factors
- Failure to meet the minimum tender condition (more than 50% of shares)
- Regulatory challenges or legal restraints (antitrust, CFIUS, or other) despite HSR clearance
- Potential competing acquisition proposals triggering a superior offer and termination fee
- Stockholder appraisal rights under Delaware law could result in higher per-share valuation
- Convertible noteholder actions (fundamental change put or conversion) could affect deal economics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-T Filing (Primary) | 0001140361-26-041224 |
| Document: ny20084254x1_exa1b.htm | 0001140361-26-041224 |
| Document: ny20084254x1_sctot.htm | 0001140361-26-041224 |
| Document: ny20084254x1_exd2.htm | 0001140361-26-041224 |
| Document: ny20084254x1_exa1e.htm | 0001140361-26-041224 |
| Document: ny20084254x1_exa5d.htm | 0001140361-26-041224 |
| Document: ny20084254x1_exa1c.htm | 0001140361-26-041224 |
| Document: ny20084254x1_exa1d.htm | 0001140361-26-041224 |
| Document: ny20084254x1_ex107.htm | 0001140361-26-041224 |
| Document: 0001140361-26-041224-index-headers.html | 0001140361-26-041224 |
| Document: 0001140361-26-041224-index.html | 0001140361-26-041224 |
| Document: 0001140361-26-041224.txt | 0001140361-26-041224 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | SC 13G/A | $36.40 | awaiting T+60 | awaiting T+60 | $36.39 (−0.03%) |
Oct 30, 2026 2d ago | SC 14D-9 | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 30, 2026 2d ago | SC TO-T | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 13, 2026 19d ago | SC 13D/A | $36.40 | awaiting T+60 | awaiting T+60 | $36.39 (+0.03%) |
Oct 8, 2026 24d ago | SC TO-C | $36.31 | awaiting T+60 | awaiting T+60 | $36.39 (+0.22%) |
Oct 8, 2026 24d ago | 144 | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 8, 2026 24d ago | 8-K | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Oct 8, 2026 24d ago | SC TO-C | $36.39 | awaiting T+60 | awaiting T+60 | $36.39 (−0.00%) |
Aug 6, 2026 12w ago | Press Release | $25.58 $36.39 | ▲ +42.26% | ▲ +43.93% | $36.39 (+42.26%) |
Jul 22, 2026 14w ago | Press Release | $25.59 $36.33 | ▲ +41.97% | ▲ +38.71% | $36.39 (+42.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers